A detailed history of Geode Capital Management, LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 3,206,390 shares of TGTX stock, worth $81.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,206,390
Previous 3,107,444 3.18%
Holding current value
$81.1 Million
Previous $47.3 Million 20.69%
% of portfolio
0.01%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$13.32 - $19.19 $1.32 Million - $1.9 Million
98,946 Added 3.18%
3,206,390 $57 Million
Q1 2024

May 13, 2024

BUY
$13.02 - $21.3 $140,589 - $229,997
10,798 Added 0.35%
3,107,444 $47.3 Million
Q4 2023

Feb 13, 2024

BUY
$6.68 - $18.81 $1.09 Million - $3.06 Million
162,820 Added 5.55%
3,096,646 $52.9 Million
Q3 2023

Nov 13, 2023

BUY
$8.36 - $26.5 $863,061 - $2.74 Million
103,237 Added 3.65%
2,933,826 $24.5 Million
Q2 2023

Aug 11, 2023

BUY
$15.48 - $35.0 $2.33 Million - $5.28 Million
150,789 Added 5.63%
2,830,589 $70.3 Million
Q1 2023

May 15, 2023

BUY
$10.23 - $19.34 $956,781 - $1.81 Million
93,527 Added 3.62%
2,679,800 $40.3 Million
Q4 2022

Feb 13, 2023

BUY
$5.01 - $11.83 $880,928 - $2.08 Million
175,834 Added 7.29%
2,586,273 $30.6 Million
Q3 2022

Nov 14, 2022

BUY
$4.57 - $8.4 $396,835 - $729,414
86,835 Added 3.74%
2,410,439 $14.3 Million
Q2 2022

Aug 12, 2022

BUY
$3.74 - $10.66 $505,397 - $1.44 Million
135,133 Added 6.17%
2,323,604 $9.88 Million
Q1 2022

May 13, 2022

SELL
$7.81 - $20.45 $947,868 - $2.48 Million
-121,366 Reduced 5.25%
2,188,471 $20.8 Million
Q4 2021

Feb 11, 2022

BUY
$15.2 - $35.51 $113,376 - $264,869
7,459 Added 0.32%
2,309,837 $43.9 Million
Q3 2021

Nov 12, 2021

BUY
$21.78 - $40.45 $3.17 Million - $5.89 Million
145,702 Added 6.76%
2,302,378 $76.6 Million
Q2 2021

Aug 13, 2021

BUY
$32.5 - $48.96 $3.55 Million - $5.35 Million
109,244 Added 5.34%
2,156,676 $83.7 Million
Q1 2021

May 12, 2021

BUY
$41.61 - $54.3 $11.2 Million - $14.6 Million
269,045 Added 15.13%
2,047,432 $98.7 Million
Q4 2020

Feb 12, 2021

BUY
$25.27 - $54.9 $3.91 Million - $8.48 Million
154,545 Added 9.52%
1,778,387 $92.5 Million
Q3 2020

Nov 13, 2020

BUY
$18.49 - $27.24 $2.28 Million - $3.36 Million
123,295 Added 8.22%
1,623,842 $43.5 Million
Q2 2020

Aug 13, 2020

BUY
$8.9 - $21.84 $1.42 Million - $3.49 Million
160,014 Added 11.94%
1,500,547 $29.2 Million
Q1 2020

May 14, 2020

BUY
$7.14 - $15.99 $1.71 Million - $3.83 Million
239,730 Added 21.78%
1,340,533 $13.2 Million
Q4 2019

Feb 13, 2020

SELL
$5.1 - $11.2 $74,164 - $162,870
-14,542 Reduced 1.3%
1,100,803 $12.2 Million
Q3 2019

Nov 12, 2019

BUY
$5.38 - $8.99 $434,252 - $725,636
80,716 Added 7.8%
1,115,345 $6.26 Million
Q2 2019

Aug 14, 2019

BUY
$6.27 - $8.65 $667,629 - $921,052
106,480 Added 11.47%
1,034,629 $8.95 Million
Q1 2019

May 14, 2019

BUY
$4.02 - $8.04 $695,234 - $1.39 Million
172,944 Added 22.9%
928,149 $7.46 Million
Q4 2018

Feb 13, 2019

BUY
$3.44 - $5.76 $242,169 - $405,492
70,398 Added 10.28%
755,205 $3.1 Million
Q3 2018

Nov 13, 2018

BUY
$5.15 - $14.0 $493,766 - $1.34 Million
95,877 Added 16.28%
684,807 $3.83 Million
Q2 2018

Aug 14, 2018

BUY
$12.5 - $15.0 $1.13 Million - $1.36 Million
90,679 Added 18.2%
588,930 $7.74 Million
Q1 2018

May 15, 2018

BUY
$8.7 - $16.8 $313,034 - $604,480
35,981 Added 7.78%
498,251 $7.08 Million
Q4 2017

Feb 13, 2018

BUY
$7.35 - $12.3 $63,937 - $106,997
8,699 Added 1.92%
462,270 $3.79 Million
Q3 2017

Nov 14, 2017

BUY
$10.0 - $12.7 $228,170 - $289,775
22,817 Added 5.3%
453,571 $5.37 Million
Q2 2017

Aug 14, 2017

BUY
N/A
430,754
430,754 $4.33 Million

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $3.67B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.